"The labels of 2 formulations of finasteride, used to treat enlarged prostate and male-pattern baldness, are being revised to indicate that additional sexual side effects may persist after the drug has been discontinued, FDA announced"
Formulary Watch
Latest News
All News
Advertisement
The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis, according to a clinical trial that appeared in the JAMA?s Archives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered.
A set of 11 evidence-based recommendations for managing pain with pharmacotherapy in patients suffering inflammatory arthritis were reported by an international panel online March 24 in Rheumatology.
"Phthalate metabolites, chemicals commonly used in plastics, cosmetics, and pharmaceuticals, were linked to an increased risk for the development of type 2 diabetes in the elderly, a recent study found. "
"Doctors debate whether men with elevated cholesterol who are otherwise healthy should still take statins, in a new series in JAMA, Dueling Viewpoints. "
The Institute for Safe Medication Practices (ISMP) is warning about the severe side effects associated with infliximab for rheumatoid arthritis, Crohn?s disease, and other autoimmune disorders.
US healthcare costs associated with neonatal abstinence syndrome (NAS) climbed from $39,400 in 2000 to $53,400 in 2009, and state Medicaid programs paid for the majority of the cases. Approximately 3.39 per 1,000 hospital births in 2009 had NAS compared with 1.20 in 2000, according to a report published online from JAMA.
Drug Watch: Multiple sclerosis
New molecular entity: FDA approved Ivacaftor, a treatment of cystic fibrosis for patients with a G551D mutation in the CFTR gene
A recent study indicated that publicly reporting quality data to CMS has not lead to a reduction in mortality.
Advertisement
With the aging of the US population, elective total hip and knee replacement operations have become more prevalent, and costs to the healthcare system for these procedures are increasing rapidly. This includes costs related to treatment of venous thromboembolism, which may be a consequence of these operations if appropriate postoperative thromboprophylaxis is not administered.
Recent FDA action (through April 2012) related to, Dihydroergotamine, Levadex inhalation aerosol, droxidopa, Northera, Amitriptyline 4% ketamine 2% cream, AmiKet, Afilbercept, ZALTRAP, Nav rAAV8 vector, Carbamazepine, Carbatrol, Vancomycin hydrochloride, Vancocin, Irbesartan, irbesartan-hydrochloriderothiazide, Avapro, Avalide, Fluvastatin, Lescol
Drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills, according to recent FDA observational (epidemiologic) studies.
Patients with coronary heart disease who used statins were at a decreased risk of depression; whether there is a cause-and effect relationship, however, merits further research, according to a study published online February 21 in The Journal of Clinical Psychiatry.
Apixiban (Eliquis) is an orally active factor Xa inhibitor. Its manufacturers are seeking FDA approval to market apixaban to reduce risk of stroke and systemic embolism in patients with nonvalvular AF (NVAF).
New formulation: FDA approved Exenatide extended-release, a once-weekly treatment (along with diet and exercise) to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings
Recent FDA Approvals (through April 2012) related to (Johnson & Johnson, AstraZeneca, Affymax, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Avioq, Hope Pharmaceuticals, Novo Nordisk, Avid Radiopharmaceuticals)
A report for the American College of Cardiology's Scientific Session & Expo
The National Association of Boards of Pharmacy, the Accreditation Council for Pharmacy Education (ACPE), and ACPE providers have teamed up to create the CPE Monitor. This new system will allow for the electronic transmission of continuing pharmacy education data.
FDA has issued a safety alert, warning patients, caregivers, and healthcare professionals about the dangers of accidental exposure to and improper storage and disposal of fentanyl patches.
As many as 80% of patients who are candidates for preventive treatments for migraine headaches could be helped by these treatments, the author of new guidelines issued by the American Academy of Neurology told Formulary.
Twice-daily dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim) was shown to be associated with lower rates of fatal and traumatic intracranial hemorrhage compared with warfarin, according to the results of a retrospective subanalysis published online, April 5, in Stroke, the Journal of the American Heart Association.
More than 75% of the nation?s opinion leaders believe that the best way to control healthcare costs is through discovering innovative ways to deliver services, according to the new NEHI Innovation Barometer survey.
Novartis has agreed with FDA to update US prescribing information on fingolimod (Gilenya) to include updated patient selection parameters based on certain cardiovascular considerations to aid in the identification of candidates for Gilenya.
FDA has strengthened its oversight of drugs after they've been approved, thanks to its updated postmarket drug safety program, according to a new report by the agency's Center for Drug Evaluation and Research.
FDA has issued a Drug Safety Communication (April 20) warning of possible risks when using blood pressure medicines containing aliskiren with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations are contraindicated in patients with diabetes.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
2
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
3
Is there a dangerous 'weekend effect' to hospitals admissions? The verdict is split | CHEST 2026
4
Experts say cost barriers and stigma keep eligible adults from lung cancer screening
5